References
1. Stahl, M., et al., Risk of recurrence and survival after
relapse in patients with Ewing sarcoma. Pediatr Blood Cancer, 2011.57 (4): p. 549-53.
2. Barker, L.M., et al., Survival after recurrence of Ewing’s
sarcoma family of tumors. J Clin Oncol, 2005. 23 (19): p.
4354-62.
3. Bacci, G., et al., Therapy and survival after recurrence of
Ewing’s tumors: the Rizzoli experience in 195 patients treated with
adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol,
2003. 14 (11): p. 1654-9.
4. Leavey, P.J., et al., Prognostic factors for patients with
Ewing sarcoma (EWS) at first recurrence following multi-modality
therapy: A report from the Children’s Oncology Group. Pediatr Blood
Cancer, 2008. 51 (3): p. 334-8.
5. Lagmay, J.P., et al., Outcome of Patients With Recurrent
Osteosarcoma Enrolled in Seven Phase II Trials Through Children’s Cancer
Group, Pediatric Oncology Group, and Children’s Oncology Group: Learning
From the Past to Move Forward. J Clin Oncol, 2016. 34 (25): p.
3031-8.
6. Exelixis, Investigator’s Brochure for Cabozantinib (XL184).2015. Edition 11.0 .
7. Yakes, F.M., et al., Cabozantinib (XL184), a novel MET and
VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis,
and tumor growth. Mol Cancer Ther, 2011. 10 (12): p. 2298-308.
8. Fleuren, E.D., et al., Expression and clinical relevance of MET
and ALK in Ewing sarcomas. Int J Cancer, 2013. 133 (2): p.
427-36.
9. Patane, S., et al., MET overexpression turns human primary
osteoblasts into osteosarcomas. Cancer Res, 2006. 66 (9): p.
4750-7.
10. Sampson, E.R., et al., The orally bioavailable met inhibitor
PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production
in a xenograft model. J Bone Miner Res, 2011. 26 (6): p.
1283-94.
11. Chuk, M.K., et al., A phase 1 study of cabozantinib in
children and adolescents with recurrent or refractory solid tumors,
including CNS tumors: Trial ADVL1211, a report from the Children’s
Oncology Group. Pediatr Blood Cancer, 2018. 65 (8): p. e27077.
12. Italiano, A., et al., Cabozantinib in patients with advanced
Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase
2 trial. Lancet Oncol, 2020. 21 (3): p. 446-455.
13. Vo, K.T., K.K. Matthay, and S.G. DuBois, Targeted
antiangiogenic agents in combination with cytotoxic chemotherapy in
preclinical and clinical studies in sarcoma. Clin Sarcoma Res, 2016.6 : p. 9.
14. Schiff, D., et al., Phase 1 dose escalation trial of the
safety and pharmacokinetics of cabozantinib concurrent with temozolomide
and radiotherapy or temozolomide after radiotherapy in newly diagnosed
patients with high-grade gliomas. Cancer, 2016. 122 (4): p.
582-7.
15. Zhen, D.B., et al., A phase I trial of cabozantinib and
gemcitabine in advanced pancreatic cancer. Invest New Drugs, 2016.34 (6): p. 733-739.
16. Saylors, R.L., 3rd, et al., Phase I study of topotecan in
combination with cyclophosphamide in pediatric patients with malignant
solid tumors: a Pediatric Oncology Group Study. J Clin Oncol, 1998.16 (3): p. 945-52.
17. Saylors, R.L., 3rd, et al., Cyclophosphamide plus topotecan in
children with recurrent or refractory solid tumors: a Pediatric Oncology
Group phase II study. J Clin Oncol, 2001. 19 (15): p. 3463-9.
18. Klega, K., et al., Detection of Somatic Structural Variants
Enables Quantification and Characterization of Circulating Tumor DNA in
Children With Solid Tumors. JCO Precis Oncol, 2018. 2018 .
19. Kieuhoa T. Vo, J.G.M., Avanthi T. Shah, Joel M. Reid, Sarah A.
Burhow, Eloise M. Graham, Fabienne Hollinger, Matthew A. Zapala, Janel
Long-Boyle, Mi-Ok Kim, Katherine K. Matthay, and Steven G. DuBois,Phase I trial of pazopanib in combination with irinotecan and
temozolomide (PAZIT) for children and young adults with advanced
sarcoma. Journal of Clinical Oncology, 2020.
20. Michela Casanova, F.B., Quentin Campbell Hewson, Guy Makin, Lynley
V. Marshall, Arnauld Verschuur, Adela Canete, Nadège Corradini, Bart
Ploeger, Udo Mueller, Hong Zebger-Gong, John Woojune Chung, and Birgit
Geoerger, Phase I study of regorafenib in combination with
vincristine and irinotecan in pediatric patients with recurrent or
refractory solid tumors. Journal of Clinical Oncology, 2020(38).
21. Weiss, A.R., et al., Pathological response in children and
adults with large unresected intermediate-grade or high-grade soft
tissue sarcoma receiving preoperative chemoradiotherapy with or without
pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2
trial. Lancet Oncol, 2020. 21 (8): p. 1110-1122.
22. Gaspar, N., et al., Phase I/II study of single-agent
lenvatinib in children and adolescents with refractory or relapsed solid
malignancies and young adults with osteosarcoma (ITCC-050)(☆). ESMO
Open, 2021. 6 (5): p. 100250.
23. McCabe, M., et al., Phase III assessment of topotecan and
cyclophosphamide and high-dose ifosfamide in rEECur: An international
randomized controlled trial of chemotherapy for the treatment of
recurrent and primary refractory Ewing sarcoma (RR-ES). Journal of
Clinical Oncology, 2022. 40 (17_suppl): p. LBA2-LBA2.